WO2014153117A3 - Anticorps dirigés contre hgf et compositions les contenant - Google Patents

Anticorps dirigés contre hgf et compositions les contenant Download PDF

Info

Publication number
WO2014153117A3
WO2014153117A3 PCT/US2014/029163 US2014029163W WO2014153117A3 WO 2014153117 A3 WO2014153117 A3 WO 2014153117A3 US 2014029163 W US2014029163 W US 2014029163W WO 2014153117 A3 WO2014153117 A3 WO 2014153117A3
Authority
WO
WIPO (PCT)
Prior art keywords
hgf
antibodies
binding fragments
compositions containing
fragments
Prior art date
Application number
PCT/US2014/029163
Other languages
English (en)
Other versions
WO2014153117A2 (fr
WO2014153117A9 (fr
Inventor
Benjamin H. Dutzar
Katie ANDERSON
Brian R. Kovacevich
Andrew L. Feldhaus
John A. Latham
Leon F. GARCIA-MARTINEZ
Original Assignee
Alder Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals, Inc. filed Critical Alder Biopharmaceuticals, Inc.
Priority to KR1020157029279A priority Critical patent/KR20150140685A/ko
Priority to EP14767985.6A priority patent/EP2964673A4/fr
Priority to JP2016503002A priority patent/JP2016516052A/ja
Priority to CA2904743A priority patent/CA2904743A1/fr
Priority to CN201480026978.3A priority patent/CN105246915A/zh
Publication of WO2014153117A2 publication Critical patent/WO2014153117A2/fr
Publication of WO2014153117A9 publication Critical patent/WO2014153117A9/fr
Publication of WO2014153117A3 publication Critical patent/WO2014153117A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps et des fragments de ceux-ci ayant une spécificité de liaison pour HGF. Un autre mode de réalisation de cette invention concerne les anticorps décrits ici, et des fragments de liaison de ceux-ci, comprenant les séquences des polypeptides VH, VL et CDR décrits dans la description, et les polynucléotides codant pour ceux-ci. L'invention concerne également des conjugués d'anticorps anti-HGF et des fragments de liaison de ceux-ci conjugués à une ou plusieurs fractions fonctionnelles ou détectables. L'invention concerne également des procédés de fabrication desdits anticorps anti-HGF et des fragments de liaison associés. Des modes de réalisation de l'invention concernent également l'utilisation d'anticorps anti-HGF, et des fragments de liaison de ceux-ci, pour le diagnostic, l'estimation et le traitement de maladies et de troubles associés à HGF.
PCT/US2014/029163 2013-03-14 2014-03-14 Anticorps dirigés contre hgf et compositions les contenant WO2014153117A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020157029279A KR20150140685A (ko) 2013-03-14 2014-03-14 Hgf에 대한 항체 및 이를 포함하는 조성물
EP14767985.6A EP2964673A4 (fr) 2013-03-14 2014-03-14 Anticorps dirigés contre hgf et compositions les contenant
JP2016503002A JP2016516052A (ja) 2013-03-14 2014-03-14 Ｈｇｆに対する抗体及びそれらを含む組成物
CA2904743A CA2904743A1 (fr) 2013-03-14 2014-03-14 Anticorps diriges contre hgf et compositions les contenant
CN201480026978.3A CN105246915A (zh) 2013-03-14 2014-03-14 Hgf抗体及含有其的组合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361781643P 2013-03-14 2013-03-14
US201361782868P 2013-03-14 2013-03-14
US61/781,643 2013-03-14
US61/782,868 2013-03-14

Publications (3)

Publication Number Publication Date
WO2014153117A2 WO2014153117A2 (fr) 2014-09-25
WO2014153117A9 WO2014153117A9 (fr) 2014-11-27
WO2014153117A3 true WO2014153117A3 (fr) 2015-01-08

Family

ID=51581767

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/029383 WO2014153166A2 (fr) 2013-03-14 2014-03-14 Utilisation thérapeutique d'anticorps contre hgf
PCT/US2014/029163 WO2014153117A2 (fr) 2013-03-14 2014-03-14 Anticorps dirigés contre hgf et compositions les contenant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029383 WO2014153166A2 (fr) 2013-03-14 2014-03-14 Utilisation thérapeutique d'anticorps contre hgf

Country Status (7)

Country Link
EP (1) EP2964673A4 (fr)
JP (1) JP2016516052A (fr)
KR (1) KR20150140685A (fr)
CN (1) CN105246915A (fr)
CA (1) CA2904743A1 (fr)
TW (2) TW201438737A (fr)
WO (2) WO2014153166A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699868B (zh) * 2017-03-01 2019-11-15 牡丹江医学院 一种蛋白质及编码其的核苷酸序列
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN112569359A (zh) * 2019-09-30 2021-03-30 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
CN115279375A (zh) 2019-11-05 2022-11-01 艾伯维公司 用于以navitoclax治疗骨髓纤维化和mpn相关病症的给药方案
WO2022228514A1 (fr) * 2021-04-29 2022-11-03 北京浩古元方生物医药科技有限公司 Anticorps anti-facteur inhibiteur de la leucémie humaine et son utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718174B2 (en) * 2006-07-14 2010-05-18 Abxign, Inc. Anti-HGF/SF humanized antibody
US20100129357A1 (en) * 2008-11-25 2010-05-27 Leon Garcia-Martinez Antibodies to il-6 and use thereof
US20130344068A1 (en) * 2010-12-01 2013-12-26 Leon F. Garcia-Martinez Methods of preventing inflammation and treating pain using anti-ngf compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2021463B1 (fr) * 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Procédé de culture permettant d'obtenir une population clonée de lymphocytes b spécifiques d'antigène
CN101460521A (zh) * 2006-06-02 2009-06-17 Aveo制药公司 肝细胞生长因子(hgf)的结合蛋白质
AU2007254942B2 (en) * 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
KR101196184B1 (ko) * 2006-06-02 2012-11-01 아베오 파마슈티컬즈, 인크. 간세포 성장 인자 (ｈｇｆ) 결합 단백질

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718174B2 (en) * 2006-07-14 2010-05-18 Abxign, Inc. Anti-HGF/SF humanized antibody
US20100129357A1 (en) * 2008-11-25 2010-05-27 Leon Garcia-Martinez Antibodies to il-6 and use thereof
US20130344068A1 (en) * 2010-12-01 2013-12-26 Leon F. Garcia-Martinez Methods of preventing inflammation and treating pain using anti-ngf compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BURGESS ET AL.: "Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met-Dependent Human Tumors'.", CANCER RESEARCH, vol. 66, 1 February 2006 (2006-02-01), pages 1721 - 1729, XP008075112 *
See also references of EP2964673A4 *

Also Published As

Publication number Publication date
JP2016516052A (ja) 2016-06-02
TW201444868A (zh) 2014-12-01
WO2014153117A2 (fr) 2014-09-25
TW201438737A (zh) 2014-10-16
CA2904743A1 (fr) 2014-09-25
WO2014153166A2 (fr) 2014-09-25
CN105246915A (zh) 2016-01-13
KR20150140685A (ko) 2015-12-16
EP2964673A4 (fr) 2017-02-22
WO2014153117A9 (fr) 2014-11-27
EP2964673A2 (fr) 2016-01-13
WO2014153166A3 (fr) 2014-12-04

Similar Documents

Publication Publication Date Title
PH12018500521A1 (en) Anti-cgrp compositions and use thereof
NZ702304A (en) Anti-pcsk9 antibodies and use thereof
WO2012075340A3 (fr) Compositions anti-ngf et leur utilisation
WO2014153117A3 (fr) Anticorps dirigés contre hgf et compositions les contenant
MX2018012470A (es) Anticuerpos anti pacap humanizados y usos de ellos.
WO2008144753A3 (fr) Anticorps anti-tnf alpha et leur utilisation
TR201905366T4 (tr) IL-6 antikorları ve bunların kullanımı.
WO2015073580A8 (fr) Anticorps spécifiques du ligand 1a de type facteur de nécrose tumorale et compositions ainsi qu'utilisations associées
AR095556A1 (es) Anticuerpos contra hgf y composiciones que contienen a los mismos
BR112015009961A2 (pt) imunoglobinas anti-vegf/dll4 com duplo domínio variável e uso destas
WO2015053871A3 (fr) Acides nucléiques codant des anticorps humains contre sialyl-lewisa
WO2011025964A3 (fr) Protéines thérapeutiques se liant à dll4
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
BR112012032778A2 (pt) "proteínas multiespecíficas e multivalentes"
PH12017500864A1 (en) Anti-notch1 antibodies
WO2011059755A3 (fr) Immunoglobulines doubles de domaine variable et utilisations de celles-ci
WO2014144280A3 (fr) Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1β et/ou il -17
WO2016100838A3 (fr) Anticorps anti-acth humanisés et leur utilisation
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
WO2009105585A3 (fr) Agents de chimiodénervation ciblés de manière postsynaptique et leurs procédés d’utilisation
WO2015187811A3 (fr) Anticorps monoclonal humain contre le ganglioside gd2
WO2011040973A3 (fr) Immunoconjugués de tnf avec des anticorps de protéine d'activation des fibroblastes et procédés et utilisations de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14767985

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2904743

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016503002

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014767985

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157029279

Country of ref document: KR

Kind code of ref document: A